FDA Coronavirus (COVID-19) Update: June 16th, 2020

Silver Spring, MD – The U.S. Food and Drug Administration is continuing  to take action in the ongoing response to the COVID-19 Coronavirus pandemic:

Today, FDA revoked the emergency use authorization (EUA) that allowed for chloroquine phosphate and hydroxychloroquine sulfate donated to the Strategic National Stockpile to be used to treat certain hospitalized patients with COVID-19 Coronavirus when a clinical trial was unavailable, or participation in a clinical trial was not feasible.

[Read more]

FDA Coronavirus (COVID-19) Update: May 19th, 2020

Silver Spring, MD – The U.S. Food and Drug Administration (FDA) today continued to take action in the ongoing response effort to the COVID-19 Coronavirus pandemic:

The FDA issued warning letters to two companies for selling fraudulent COVID-19 Coronavirus products, as part of the agency’s effort to protect consumers.

[Read more]

FDA Coronavirus (COVID-19) Update: April 14th, 2020

Silver Spring, MD – The U.S. Food and Drug Administration (FDA) has announced the following actions taken in its ongoing response effort to the COVID-19 Coronavirus pandemic:

Given the anticipated increase in demand for chloroquine phosphate and hydroxychloroquine sulfate, the FDA is taking steps to ensure that adequate supply of these drug products is available for patients.

[Read more]